A global alliance, C-BRAIN (Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration), released three open-source AI tools designed to accelerate treatment discovery for Alzheimer’s and other neurodegenerative diseases. The effort is spearheaded by Washington University School of Medicine in St. Louis. The tools are positioned for use across multiple parts of the discovery workflow, with the consortium framing the releases as a way to reduce barriers to computational research in neurodegeneration. Open-source distribution signals a push for broader adoption by academic and industry groups developing therapeutics. For biotech teams, the immediate value is access to AI software components that can be incorporated into target discovery, candidate prioritization, or biomarker-related analyses.